Blockonomi

TLDR:
The LIBRA scandal criminal case against Javier Milei, Karina Milei, Hayden Davis, and eight others was dismissed after the judge found no offense established.
Judge Marcelo Martínez de Giorgi ruled that a token price collapse and investor losses, without a provable deceptive act, did not establish criminal fraud.
Investigators found no proof that Karina Milei received payment for arranging access to the president, while Hayden Davis was also dismissed from the case.
Opposition lawmakers criticized the case closure, while disputes over removed investor complainants remain pending before a higher Argentine court.
Argentina has dismissed the criminal case behind the LIBRA scandal. The ruling covers President Javier Milei, Karina Milei, Hayden Davis, and eight others.
Federal Judge Marcelo Martínez de Giorgi issued the 60-page ruling on October 23, after prosecutor Eduardo Taiano sought dismissal. The inquiry began in February 2025.
Milei promoted LIBRA on X during its launch, framing it as support for Argentine businesses. The token rallied briefly, then crashed. He later removed his post.
The case drew scrutiny because Milei was president. Loss estimates vary, with some reports exceeding $200 million. The court found no evidence of fraud.
LIBRA Scandal Dismissal Ends Criminal Case in Argentina
The LIBRA scandal investigation examined claims of fraud, influence peddling, abuse of authority, and conflicts involving public office. The judge accepted the prosecutor’s view that the facts did not satisfy the legal elements of those offenses.
Argentine Judge Drops LIBRA Criminal Probe Against President Milei and Hayden Davis
According to Reuters, Argentine federal judge Marcelo Martínez de Giorgi has dropped the criminal investigation into President Javier Milei, his sister Karina Milei, and U.S. businessman Hayden… pic.twitter.com/LxME8TuBuM
— Wu Blockchain (@WuBlockchain) October 24, 2026
The court said neither a price decline nor investor losses alone establish criminal fraud. It found no identified false statement that directly persuaded buyers to acquire LIBRA. The ruling also said public attention surrounding a promoter does not automatically prove a deceptive scheme. It said the investigation failed to show an induced error and direct financial harm arising from such a deception.
For Milei, the judge recognized that his office gave the launch added visibility. Yet the ruling said that institutional influence, by itself, was not evidence of fraud. Investigators did not find that the X post was an official act or used state resources. The court said there was no record of an administrative order or government contract tied to the promotion.
The judge also dismissed the case against Karina Milei, the president’s secretary general. Investigators examined unsigned files recovered from Mauricio Novelli’s phone. They did not establish that she received payment for arranging meetings with the president. The court said the material did not prove a remunerated arrangement or influence peddling.
Davis described himself as a launch adviser and denied wrongdoing. The judge found insufficient evidence of criminal coordination between Davis and government officials. The dismissal also covered Novelli, Manuel Terrones Godoy, Sergio Morales, Julian Peh, María Alicia Rafaele, María Pía Novelli, Camilo Rodríguez Blanco, and Orlando Mellino. The case file was closed.
Why the LIBRA Scandal Ruling Drew Political Criticism
Reaction to the LIBRA scandal ruling split sharply along political lines. The presidential office called it proof of Milei’s innocence. Milei described the case as a political and media operation against him.
Opposition lawmakers challenged the closure. Deputy Maximiliano Ferraro criticized the failure to call the defendants for formal questioning. He also said investigators did not complete measures sought by affected investors.
Those criticisms do not change the court’s ruling. However, challenges over the removal of private complainants from the Argentine proceedings remain before the Federal Criminal Cassation Court. That dispute concerns their participation, not an established reversal of the dismissal.
The LIBRA scandal has also produced litigation outside Argentina. A New York federal court dismissed a separate class action in September involving Kelsier, Davis, former Meteora CEO Benjamin Chow, and Meteora. The case was dismissed on procedural and substantive grounds.
The Argentine decision did not award compensation to token buyers. Nor did it determine a single final investor-loss figure. It concluded only that the evidence gathered did not establish criminal liability under the offenses examined. It did not directly assess the token’s commercial merits.
Earlier reporting described attempts to trace digital assets and obtain records from cryptocurrency platforms. Some investigative requests were incomplete or produced limited results. Authorities also could not determine the content of certain calls between Milei and Novelli near the launch.
The post LIBRA Scandal Case Against Milei Dismissed by Argentine Judge appeared first on Blockonomi.

TLDR:
Swell paused swETH and rswETH deposits and withdrawals at 2:39 a.m. ET on Friday, October 23.
The swETH contract reported about 1.203 ETH, roughly 6% above the last clean rate of 1.133 ETH.
On-chain analyst Spreek suspected compromised admin keys and found malicious upgrade contracts.
Swell stated that no ETH has left the affected contracts, but it gave no cause or reopening date.
Swell pauses swETH and rswETH deposits and withdrawals after the contracts reported abnormally high exchange rates. The Ethereum staking protocol announced the halt early Friday, October 23.
The swETH contract showed a rate near 1.203 ETH, while rswETH stood near 1.138 ETH. Both figures sit roughly 6% and 5% above normal levels.
Swell said no ETH has left the affected contracts. However, the team has not confirmed a cause or given a reopening date.
Exchange Rates Rise Above Normal Levels
Swell announced the pause at 2:39 a.m. ET on Friday. The team said its next step is returning the net asset value (NAV) of both tokens to the correct level. Deposits and withdrawals stay closed until then.
At 4:48 p.m. ET, Unchained’s read of the contracts showed swETH at about 1.203 ETH. The rswETH rate stood near 1.138 ETH. On-chain analyst Spreek had identified the last clean rates as 1.133 ETH and 1.082 ETH.
On decentralized exchanges, swETH traded near 1.089 WETH in a Uniswap pool with about $143,000 in liquidity. Meanwhile, rswETH traded near 1.029 WETH on Curve. Both market prices sit below the rates the contracts report.
According to DefiLlama, swETH holds about $29 million. The rswETH token holds roughly the same amount. So far, Swell has not offered guidance on trading or providing liquidity.
Admin Key Compromise Suspected, Cause Unconfirmed
Spreek posted on Wednesday, October 21, that admin keys for both tokens appeared compromised. He wrote that NAV was rising by “max 1% (unbacked) each hour” at the time.
He also identified four malicious upgrade contracts able to take about 2,500 ETH. None had been queued through Swell’s multisig.
Odysseus, founder of Phylax Systems, described the incident as “BOT-key abuse.” He added that the 2,513 ETH held “is NOT confirmed loss.” His comments came shortly after Spreek’s initial warning.
Swell responded at 11:03 p.m. ET that it was working with security partners. The team stated that “no ETH has left” the swETH or rswETH withdrawal or deposit contracts. It later wrote, “All funds are safe.” In addition, the team warned that such events can bring more phishing attempts.
Both researchers raised a possible link to Railway, a cloud deployment platform. Railway said in an October 21 disclosure that an “unauthorized third party” may have read some encrypted environment variables.
Its disclosure does not mention Swell, and Swell has not confirmed a connection. Spreek’s report, which he said was AI-written and not fully checked, found that Aave, Spark, and Fluid accepted neither token. A Morpho market had about 34 ETH available to borrow.
The post Swell Pauses swETH and rswETH Deposits and Withdrawals Over Inflated Exchange Rates appeared first on Blockonomi.

TLDR:
Arthur Hayes says Hyperliquid proved on-chain perpetual futures have real demand and a working product.
He sees HYPE’s main risk as underperforming ETH and ZEC rather than necessarily losing money.
Perpetual DEXs face rising competition as products, features, and fees become increasingly similar.
Hayes sold all his HYPE and NEAR holdings just days after publicly setting a $150 HYPE price target.
Arthur Hayes, the founder of BitMEX, said Hyperliquid has proven that demand exists for on-chain perpetual futures markets.
On October 16, however, he warned that HYPE has become a consensus trade, which has weakened its risk-reward profile.
According to Hayes, the main danger is not a price collapse. Instead, HYPE may trail other crypto assets, including ETH and ZEC, over the coming period. His comments came in a post that praised the product but questioned the investment case.
Why Hyperliquid Faces Tougher Competition
Arthur Hayes acknowledged that Hyperliquid built a product traders actually use. Trading volume is present, and the platform works as intended. He also said he is willing to use its products as a consumer. Even so, he does not want to take part as an investor.
Arthur Hayes: HYPE Could Significantly Underperform ETH and ZEC
On October 16, BitMEX founder Arthur Hayes @CryptoHayes stated that Hyperliquid has demonstrated genuine demand for on-chain perpetual futures markets. However, as the sector has become a consensus trade, HYPE's… pic.twitter.com/HwmsjbR5QT
— Wu Blockchain (@WuBlockchain) October 23, 2026
A great product does not always translate into a strong investment, according to Hayes. Perpetual DEXs now face rising competition as their offerings become more alike.
Centralized exchanges, traditional exchanges, and a growing list of decentralized rivals all offer similar products. In this setting, features and fees are easy to match.
When rivals match features and fees, returns on capital tend to shrink. As a result, success depends on execution, distribution, incentives, and token economics.
Hayes sees this as a difficult setup for investors to underwrite. Each of these factors can shift quickly as new platforms launch.
Hayes also pointed to HYPE’s reputation as a widely recognized perp-DEX success story. Because the trade is crowded, he believes the token offers less room to re-rate. The question, in his view, is whether HYPE delivers the best risk-adjusted return from here.
Why ETH and ZEC May Offer Better Setups
Arthur Hayes argued that HYPE could underperform without falling in price. Holders may lose ground simply because other assets rise faster.
This is the core risk he described, rather than a direct loss of capital. Relative performance, therefore, matters more than absolute price in his view.
ETH has the scale, security, and institutional DeFi narrative to attract capital. If the market rotates back toward large-cap crypto, it could benefit.
Hayes sees that setup as stronger than HYPE’s current position. He treats ETH as a more established option for investors seeking exposure.
ZEC offers a different kind of bet. It is a higher-risk way to express demand for privacy and scarce assets. Hayes noted that both ETH and ZEC could surprise investors if liquidity expands. He added that being early to a crowded winner may appeal less when capital chases upside.
Arthur Hayes previously set a $150 price target for HYPE. Days later, he announced that he had sold all his HYPE and NEAR holdings.
The post Arthur Hayes Warns HYPE Could Underperform ETH and ZEC appeared first on Blockonomi.

TLDR
BeOne’s liver cancer drug posts a 36% response rate in a Phase 1 clinical study.
BGB-B2033 shows a 74.1% six-month response durability rate at its target dose.
BeOne’s lung cancer ADC delivers a 56% response rate in CEA-high tumor patients.
PRMT5 inhibitor BGB-58067 records 30.8% intracranial responses in lung cancer.
ONC shares slip 1.21% to $377.63 despite promising new ESMO oncology trial results.
BeOne Medicines reported a 36% liver cancer response rate as new clinical results strengthened its oncology drug pipeline. The company presented findings across liver, lung, and breast cancers at the ESMO Congress 2026 in Madrid. Meanwhile, BeOne Medicines AG (ONC) stock fell 1.21% to $377.63, losing $4.64 despite progress across several experimental treatments.
BeOne Medicines AG, ONC
BeOne Medicines Reports 36% Liver Cancer Response Rate in Phase 1 Trial
BeOne Medicines presented updated Phase 1 results for BGB-B2033, an experimental treatment targeting advanced hepatocellular carcinoma. The treatment achieved a confirmed objective response rate of 36% at the selected Phase 3 dose. Moreover, the results exceeded the approximately 5% response rates associated with certain late-line tyrosine kinase inhibitors.
The study included 94 patients, with 93.6% previously receiving PD-(L)1 immunotherapy. Additionally, 61.7% had undergone treatment with both immunotherapy and a tyrosine kinase inhibitor. At the selected dose, researchers estimated a six-month confirmed response durability rate of 74.1%.
Safety findings also supported further development, with 5.3% of patients experiencing severe treatment-related adverse events. Only 2.1% discontinued treatment because of treatment-related complications across the tested dose levels. Furthermore, BeOne plans to begin global registrational trials before the end of 2026.
BeOne Advances Lung Cancer Treatments With Strong Early Clinical Results
BeOne also released initial clinical findings for BGB-58067, an experimental PRMT5 inhibitor targeting MTAP-deficient cancers. Among 75 evaluable lung cancer patients, the treatment achieved a confirmed response rate of 25.3%. Additionally, researchers recorded a disease control rate of 76%, indicating activity beyond confirmed tumor responses.
The treatment achieved a 38.5% response rate among patients with EGFR wild-type lung cancer. Meanwhile, median progression-free survival reached 7.7 months across the broader non-small cell lung cancer cohort. Researchers also recorded a 30.8% intracranial response rate among patients with untreated, asymptomatic brain metastases.
Separately, BeOne reported encouraging findings for BG-C477, its internally developed antibody-drug conjugate targeting CEA-expressing tumors. The treatment achieved a 56% confirmed response rate among 25 patients with high CEA expression. Furthermore, its disease control rate reached 88%, supporting plans for additional clinical development during 2027.
BeOne Expands Breast Cancer Pipeline Through Phase 3 KANDELA-302 Trial
Beyond liver and lung cancer, BeOne continues advancing BGB-43395, an experimental selective CDK4 inhibitor. The company launched enrollment for its global Phase 3 KANDELA-302 breast cancer trial in May 2026. The study targets patients with HR-positive, HER2-negative advanced or metastatic breast cancer receiving first-line treatment.
Researchers will compare BGB-43395 plus letrozole against three established CDK4/6 inhibitors combined with letrozole. These comparison treatments include abemaciclib, palbociclib, and ribociclib, which already serve important roles in breast cancer care. The trial will measure progression-free survival as its primary endpoint and overall survival as a key secondary endpoint.
Meanwhile, BeOne continues expanding its solid tumor portfolio beyond its established blood cancer operations. The FDA previously granted BGB-B2033 Fast Track and Orphan Drug designations for liver cancer. Together, the latest clinical findings establish several development milestones, although larger trials must confirm the early treatment results.

The post BeOne Medicines AG (ONC) Stock: 36% Liver Cancer Response Rate Fuels Breakthrough Potential appeared first on Blockonomi.

TLDR
Tesla Semi enters volume production, opening the door to commercial fleet growth.
Tesla and Nvidia commit $2.8B to expand advanced chip substrate production.
Samsung deal backs Tesla’s autonomous driving chips and Optimus robot hardware.
Tesla’s Q3 net income falls to $787M as expansion adds fresh cost pressures.
TSLA slips 0.63% to $372.22 despite Semi progress and chip supply investment.
Tesla began volume production of its Semi truck and joined Nvidia in a $2.8 billion chip substrate investment. Both moves support Tesla’s expansion into commercial transport, autonomous driving, and humanoid robots. Meanwhile, TSLA fell 0.63% to $372.22, losing $2.36 after morning selling erased early gains.
Tesla, Inc., TSLA
Tesla Semi Moves Beyond Pilot Production
Tesla moved the Semi beyond pilot production into commercial-scale manufacturing of its electric truck. The shift extends its reach into freight transportation and large commercial fleets. Moreover, higher output could help the company compete in the electric trucking market.
The Semi adds heavy trucks to Tesla’s passenger vehicles, battery systems, and charging network. Fleet operators need reliable vehicles, charging facilities, and service support for daily operations. Therefore, expansion depends on manufacturing capacity, delivery schedules, and infrastructure for business customers.
Tesla sells vehicles and energy products across the United States, China, and other regions. The new Semi output adds another production line to its existing manufacturing operations. Meanwhile, expanding truck deliveries may create additional demand for commercial charging and energy services.
Tesla and Nvidia Fund $2.8 Billion Chip Supply Expansion
Tesla and Nvidia announced a combined $2.8 billion investment in Samsung Electro-Mechanics for chip substrates. These components connect processors to the electronics that support advanced computing systems. The investment targets hardware for autonomous driving technology and Tesla’s Optimus humanoid robot.
The agreement reportedly includes five years of priority supply access for advanced substrates. That arrangement supports production planning for Tesla’s custom chips and related hardware. Additionally, greater supply capacity could ease shortages as computing demand increases.
Tesla uses specialized processors in vehicles and hardware projects, creating demand for advanced components. Nvidia’s involvement extends the project beyond Tesla’s automotive business into wider computing supply chains. Together, the firms aim to secure manufacturing capacity for systems requiring specialized electronics.
Falling Quarterly Profit Puts Expansion Costs in Focus
Tesla reported third-quarter 2026 net income of $787 million, down from $1.37 billion a year earlier. The decline reflects ongoing profitability challenges amid spending on vehicles, chips, and production. Moreover, new factories and equipment can raise costs before production generates substantial revenue.
Those expenses test Tesla’s ability to turn its larger manufacturing footprint into stronger earnings. Semi output must grow while chip investments support products that reach commercial markets. Meanwhile, the company continues funding its existing vehicle, battery, and energy operations.
One valuation model cited in the analysis estimates Tesla’s fair value at $408 per share. The estimate remains separate from its trading price and depends on future performance. Ultimately, revenue growth and operating costs will determine the financial impact of these projects

The post Tesla (TSLA) Stock: Semi Production Ramps Up as $2.8B AI Chip Deal Fuels Growth Hopes appeared first on Blockonomi.

TLDR
Roche stock jumps 2.60% as Phase 3 kidney drug results boost market momentum.
Sefaxersen cuts proteinuria by 43.1% in a pivotal Phase 3 IgA nephropathy trial.
Phase 3 data show no new safety signals for Roche’s monthly kidney treatment.
More sefaxersen patients see blood in urine resolve than those given a placebo.
Roche awaits two-year kidney function data as sefaxersen advances toward review.
Roche Holding AG reported positive Phase 3 results for its experimental kidney disease treatment, sefaxersen, showing significant reductions in proteinuria. Roche Holding AG (RHHBY) stock climbed 2.60% to $61.17, gaining $1.55 following strong midday and late-session buying. Meanwhile, the clinical findings strengthened the drug’s development prospects for patients with primary IgA nephropathy.
Roche Holding AG, RHHBY
Roche Reports 43.1% Proteinuria Reduction in Phase 3 Trial
Roche’s Genentech division presented new findings from the ongoing Phase 3 IMAgINATION study at ASN Kidney Week 2026. The trial evaluated sefaxersen in adults with primary IgA nephropathy who continued receiving optimized standard treatment. Results showed a 43.1% reduction in proteinuria relative to placebo after 37 weeks of treatment.
Researchers measured proteinuria through the 24-hour urine protein-to-creatinine ratio, a key marker of kidney damage. Moreover, the results reached statistical significance with a P-value below 0.0001 and a 95% confidence interval of 32.5%–52.0%. Lower proteinuria levels generally indicate better prospects for preserving kidney function over time.
The study also examined hematuria, a condition involving blood in the urine among patients with kidney disease. At week 37, more patients receiving sefaxersen achieved hematuria resolution than those receiving placebo. Additionally, researchers observed consistent proteinuria reductions across all prespecified patient subgroups.
Sefaxersen Shows Favorable Safety Results as Roche Advances Development
Sefaxersen targets complement factor B in the liver to address mechanisms associated with IgA nephropathy progression. The investigational treatment uses a once-monthly subcutaneous injection and supports patient self-administration. This approach could reduce treatment frequency while offering another option alongside existing kidney disease therapies.
Genentech reported that patients generally tolerated sefaxersen well throughout the study’s initial evaluation period. Furthermore, researchers identified no new safety signals compared with findings from the earlier Phase 2 study. These findings support continued clinical development, although regulators have not yet approved the treatment.
The IMAgINATION study will continue under blinded conditions to assess longer-term changes in kidney function. Researchers will measure estimated glomerular filtration rate at week 105, covering approximately two years of treatment. Roche also plans to share clinical findings with health authorities as it pursues potential regulatory approval.
Roche Holding AG Stock Gains as Kidney Disease Pipeline Progresses
Primary IgA nephropathy, also called Berger’s disease, causes progressive inflammation and damage within the kidneys’ filtering structures. The disease commonly affects younger adults, and doctors typically diagnose patients before age 40. Globally, at least 25 adults per million develop the condition annually.
The disease can eventually cause kidney failure, creating substantial long-term treatment needs for affected patients. Up to 50% of patients develop end-stage kidney disease within 20 years of diagnosis. Consequently, effective treatments that preserve kidney function could help reduce future dialysis and transplantation requirements.
Roche’s latest clinical results add another development milestone to its kidney disease research program. However, the ongoing trial must still establish the treatment’s longer-term effects on kidney function. The upcoming week 105 findings will provide further evidence as Roche advances sefaxersen toward potential regulatory review.

The post Roche Holding AG (RHHBY) Stock Rallies 2.60% Following Positive Phase 3 Kidney Drug Results appeared first on Blockonomi.

TLDR
CELC stock fell 0.49% to $65.25, then dipped another 1.39% after hours to $64.34.
Gedatolisib triplet delivers 21.5 months without progression in one key subgroup.
Triplet response rate reaches 59%, versus 33% for the control treatment group.
Gedatolisib dropout rates hit 5% and 4%, versus 19% for alpelisib treatment.
Eight-study analysis favors gedatolisib regimens in progression-free survival.
Celcuity reported promising breast cancer treatment results from its Phase 3 VIKTORIA-1 trial, strengthening the outlook for gedatolisib. New analyses showed longer disease control and higher response rates across several patient groups. However, CELC stock declined during regular trading and extended its losses after the closing bell.
Celcuity (CELC) Stock Falls Despite Positive Phase 3 Results
Celcuity shares slipped 0.49% to $65.25, a decline of $0.32 during the regular session. The stock then lost another 1.39% in after-hours trading and reached $64.34. The decline followed a volatile session despite the company’s latest clinical findings.
Celcuity Inc., CELC
Celcuity develops targeted treatments for solid tumors, with gedatolisib central to its breast cancer program. The company presented fresh findings at the European Society for Medical Oncology (ESMO) Congress on October 24, 2026. Barbara Pistilli of Gustave Roussy presented the new PIK3CA-mutant subgroup results.
The Phase 3 study tested gedatolisib combinations in patients with advanced HR-positive, HER2-negative breast cancer. Researchers compared gedatolisib combinations with existing treatment options, including alpelisib plus fulvestrant. The findings support Celcuity’s development plans, although the results do not establish regulatory approval.
Celcuity Phase 3 Trial Shows Longer Progression-Free Survival
Patients without liver metastases recorded 21.5 months of median progression-free survival with the gedatolisib triplet. By comparison, the alpelisib and fulvestrant control group reached 9.1 months. The trial reported a hazard ratio of 0.46 and a p-value of 0.0016.
Among patients with liver metastases, the triplet delivered 9.1 months, compared with 4.6 months for controls. Meanwhile, the gedatolisib doublet achieved 11.1 months for that subgroup. Both regimens showed statistically significant differences against the control in these patients.
Furthermore, triplet recipients without visceral metastases reached 21.5 months versus 9.2 months with standard treatment. Patients with visceral metastases recorded 9.8 months on the triplet, compared with 5.6 months for controls. These comparisons demonstrated benefits across disease locations, although subgroup sizes differed.
Gedatolisib Response Rates and Safety Strengthen Growth Outlook
In the PIK3CA-mutant cohort, the triplet achieved a 59% response rate, compared with 33% for controls. The doublet produced a 43% response rate, while triplet responses lasted a median 19.4 months. The alpelisib combination recorded a median response duration of 7.5 months.
Celcuity also reported a 39% response rate for the triplet in patients with PIK3CA wild-type tumors. The doublet reached 34%, while fulvestrant alone reached 1%. Moreover, treatment-emergent adverse events prompted gedatolisib discontinuation in 5% of triplet patients and 4% of doublet patients.
By contrast, 19% of patients discontinued alpelisib because of treatment-emergent adverse events. A separate analysis of eight trials also favored gedatolisib combinations over other regimens on progression-free survival measures. Together, these findings strengthen Celcuity’s clinical development outlook, although indirect comparisons cannot replace direct head-to-head trials.

The post Celcuity Inc. (CELC) Stock: Promising Phase 3 Breast Cancer Data Fuels Growth Hopes appeared first on Blockonomi.

TLDR:
Crypto prediction markets on Kalshi and Polymarket reached a record $2.7 billion in weekly notional volume, largely from short-term Bitcoin and other crypto price contracts.
Bloomberg reported that crypto ranked second to sports on both platforms, although the report did not break down volume by asset, venue, or contract.
Coinbase’s event-contract product is operated by Kalshi, giving the exchange access to markets without running the underlying marketplace itself.
State disputes over sports-related contracts could influence expansion; Michigan’s agreement with Coinbase limited sports contracts but did not resolve the wider legal question.
Crypto prediction markets on Kalshi and Polymarket logged a combined $2.7 billion in weekly notional volume last week. Bitcoin and other short-term crypto price contracts drove much of that volume. Crypto ranks second only to sports on both platforms said. The record reflects participation in event-based contracts tied to digital-asset prices.
According to Dune Analytics data cited by Bloomberg, crypto exchanges are seeking new activity as spot trading volumes decline. Coinbase offers Kalshi-powered crypto prediction markets to eligible customers. Legal challenges to sports contracts in U.S. states could influence how widely exchanges choose to expand.
Crypto Prediction Markets Set a Weekly Volume Record
The report identifies short-term price moves as a draw. A contract ties a position to an outcome over a specified period, so activity can build around Bitcoin and other token prices. These crypto prediction markets track contract turnover, rather than investment flows into coins. The weekly total covers event contracts on Kalshi and Polymarket, not spot purchases or sales on crypto exchanges. Together, these categories measure activity separately from spot trading.
Bitcoin Price Bets Help Push Weekly Crypto Volume on Kalshi and Polymarket to Record $2.7B
Bloomberg, citing data compiled by a Dune Analytics user, reported that weekly notional volume in crypto-related contracts on Kalshi and Polymarket hit a record $2.7 billion last week,… pic.twitter.com/pAS4rbuQAR
— Wu Blockchain (@WuBlockchain) October 24, 2026
Notional volume counts the face value of contracts traded; it is not the amount users deposited or the platforms’ revenue. Contracts can change hands before resolution, adding turnover without creating a new event. Crypto prediction markets can report high activity even when deposits, unique participants, or concentration among traders remain unknown. The number measures gross trading activity, not the amount of capital at risk. It also cannot show whether traders expect Bitcoin prices to rise or fall.
Crypto ranked second only to sports on both platforms, Bloomberg reported. That places the category ahead of other event types, while sports remained the largest source of activity. Bitcoin’s continuous price movement creates frequent outcomes for contracts with short time horizons, and other tokens widen the range of markets. The headline total alone cannot show whether activity clustered around one venue or coin. One week’s volume does not establish whether that pace will persist.
Bitcoin Bets Drive Crypto Exchanges Toward Prediction Markets
Exchanges are moving into crypto prediction markets as spot activity cools. The Financial Times reported that crypto companies are adding prediction products while spot trading volumes have weakened. Some are building venues; others are partnering with established operators. Event contracts offer another product inside familiar trading apps, helping platforms seek activity beyond spot trades and compete for customer attention.
Coinbase’s crypto prediction markets are operated by Kalshi, according to Coinbase’s help center. The partnership gives Coinbase access to event contracts without building an exchange operator itself. Coinbase’s markets cover crypto prices and other outcomes, subject to regional availability and eligibility. Coinbase says BTC and ETH price contracts settle using a 60-second CF Benchmarks average.Kalshi determines outcomes under each contract’s rules. The arrangement shows how dedicated operators can power prediction products inside broader financial platforms.
Sports contracts face legal challenges in several states. Regulators argue that event contracts tied to games fall under state gambling laws, while platforms cite federal derivatives oversight. Michigan’s gaming regulator said Coinbase agreed to stop offering new sports contracts in the state and close existing positions by October 10. The restriction applied to sports contracts, not all event markets. The agreement did not settle the wider dispute. As reported, dozens of states have taken legal action over sports-related contracts.
These disputes may shape how far crypto exchanges expand. State-by-state restrictions can complicate nationwide launches, while unclear product boundaries raise compliance costs. Coinbase’s Michigan agreement shows that access to one category can be limited even as the broader product grows. Exchanges must weigh expected demand against legal risk before adding markets or opening them in new jurisdictions. Court rulings could change product availability.
The post Crypto Prediction Markets Set New $2.7B Weekly Volume Record appeared first on Blockonomi.

TLDR
LLY stock drops 2.54% to $1,273.46 despite upbeat ovarian cancer trial data.
Sofe-M combination delivers a 79.3% response rate in Phase 1 ovarian cancer study.
All evaluable patients achieved disease control in Lilly’s early-stage trial.
Severe neutropenia affected 42% as dose reductions reached 42% in the study.
Lilly advances Sofe-M into three Phase 3 trials across ovarian cancer groups.
Eli Lilly reported a 79.3% response rate for its experimental ovarian cancer treatment, but its stock declined despite the positive findings. Eli Lilly (LLY) stock fell 2.54% to $1,273.46, losing $33.23 as selling pressure erased early gains. However, shares recovered 0.44% to $1,279.00 in after-hours trading, while the company advanced its ovarian cancer research.
Eli Lilly and Company, LLY
Eli Lilly Reports 79.3% Response Rate in Ovarian Cancer Trial
Eli Lilly announced new Phase 1 results for sofetabart mipitecan, also known as Sofe-M, combined with bevacizumab. The treatment achieved a confirmed objective response rate of 79.3% among patients with measurable platinum-sensitive ovarian cancer. Additionally, the combination achieved a 100% disease control rate, supporting further clinical development.
The study enrolled 33 women with platinum-sensitive ovarian cancer who had undergone several previous treatments. Among 29 patients with measurable disease, six achieved complete responses, while 17 experienced partial responses. Furthermore, researchers observed similar response rates across different FRα expression levels and previous PARP inhibitor exposure.
Patients had received a median of three previous treatment regimens before joining the study. Meanwhile, 67% had previously received PARP inhibitors, and 70% had undergone bevacizumab treatment. Researchers had not reached median response duration or progression-free survival at the July 6, 2026, data cutoff.
Sofe-M Targets Cancer Cells as Safety Results Support Development
Sofe-M uses an antibody-drug conjugate to target folate receptor alpha, a protein commonly found on ovarian cancer cells. The treatment delivers exatecan, a chemotherapy agent, directly to targeted cells through a specialized linker. Consequently, the drug aims to disrupt cancer cell DNA replication and limit tumor growth.
The combination produced adverse events consistent with the established safety profiles of both medicines. Nosebleeds and nausea each affected 73% of patients, while anemia occurred in 58% and neutropenia affected 55%. Additionally, 42% experienced severe neutropenia, while 24% developed severe anemia.
Researchers reported neuropathy in 9% of patients, with no severe cases during the study. However, adverse events required dose reductions in 42% of participants, and 6% discontinued treatment. The study identified no new safety signals, although the findings came from a small early-stage patient group.
Eli Lilly Advances Phase 3 Trials Following Positive Results
Eli Lilly continues developing Sofe-M through its global Phase 3 FRAmework-01 clinical program. The program includes three trials covering platinum-resistant and platinum-sensitive ovarian cancer across different treatment histories. These studies will further evaluate treatment effectiveness and safety in larger patient populations.
Part A examines Sofe-M alone in patients with platinum-resistant ovarian cancer. Meanwhile, Part B evaluates Sofe-M with bevacizumab in patients whose disease progressed during or shortly after PARP inhibitor treatment. Part C studies the same combination in platinum-sensitive patients without previous PARP inhibitor exposure.
The company works with international oncology research groups to conduct the Phase 3 program. Its partners include ENGOT, the GOG Foundation, and the Asia-Pacific Gynecologic Oncology Trials Group. Although LLY shares declined during regular trading, the latest findings expanded the clinical evidence supporting Sofe-M’s development.

The post Eli Lilly (LLY) Stock: Slips 2.54% Despite Promising Phase 1 Ovarian Cancer Results appeared first on Blockonomi.

TLDR
SGML stock jumps 4.68% to $7.83 after Sigma Lithium extends $100M debt maturity.
Sigma Lithium pushes its $100M loan deadline to June 2027, easing repayment pressure.
Sigma Lithium produces 7,090 tonnes of concentrate after restarting October 5.
Sigma Lithium targets 330,000 tonnes in annualized production by late 2027.
Sigma Lithium cuts total debt 40% to $125M after repaying over $90M since 2024.
Sigma Lithium Corporation (SGML) stock surged 4.68% to $7.83, gaining $0.35 as strong afternoon buying lifted shares toward intraday highs. The gain followed the company’s agreement to extend its $100 million debt maturity by six months. The extension gives Sigma Lithium more time to increase lithium production and strengthen cash flow.
Sigma Lithium Corporation, SGML
Sigma Lithium Extends $100M Debt Maturity to June 2027
Sigma Lithium secured a six-month extension on its $100 million senior secured debt facility with Synergy Capital. The agreement moves the repayment deadline from December 2026 to June 2027 without changing the existing interest rate. Moreover, the facility retains its annual interest rate of SOFR plus 6.95%, alongside existing covenants and default provisions.
The revised schedule extends the maturity of approximately 93% of the company’s debt to June 2027. Sigma Lithium gains additional time to generate operating cash flow before meeting its repayment obligations. The agreement also supports the company’s production recovery following its recent operational restart in Brazil.
Sigma Lithium has reduced its debt obligations significantly over the past two years through operating cash generation. Since the second quarter of 2024, the company has repaid more than $90 million in outstanding debt. As a result, total debt declined approximately 40% to $125 million as of October 21, 2026.
Sigma Lithium Restarts Production and Targets 330,000 Tonnes
Sigma Lithium resumed operations on October 5 after a Brazilian federal court reinstated its environmental licenses. Since restarting production, the company produced 7,090 tonnes of lithium oxide concentrate through October 22. This output marks progress in restoring operations after the earlier interruption.
Sigma Lithium maintains its annualized production target of 330,000 tonnes by the end of 2027. The company plans to use its existing Cleantech Industrial Plant and recycling circuits to support higher production volumes. Additionally, management expects stronger production and current lithium prices to support operating cash flow.
Sigma Lithium will release its third-quarter 2026 operating and financial figures by November 13. The upcoming report will cover production volumes, sales, realized lithium prices, operating costs, and cash balances. These figures will provide further details about the company’s financial position and production performance before its next repayment deadline.
Sigma Lithium Expands Economic Contribution in Brazil
Beyond production, Sigma Lithium maintains a significant economic presence in Brazil’s Jequitinhonha Valley. The company reports supporting approximately 19,000 jobs and 80,000 family members across its regional operations. Furthermore, its activities span 12 municipalities and contribute to local employment and business development.
Regional economic figures show substantial growth in municipalities surrounding Sigma Lithium’s operations. Araçuaí recorded 123% growth in GDP per capita, while Itinga registered a 110% increase. Additionally, the region recorded 9,410 new business registrations between January 2023 and March 2026.
Sigma Lithium also funds community programs covering water access, education, farming, and women’s entrepreneurship. Its microcredit initiative has supported more than 2,000 women, while drought programs have assisted thousands of rural residents. Meanwhile, the company’s education projects support approximately 776 children through improved schools, facilities, and extracurricular programs.

The post Sigma Lithium (SGML) Stock: Surges 4.68% as $100M Debt Extension Boosts Financial Flexibility appeared first on Blockonomi.

TLDR
Oracle shares gain 0.49% as its $1 billion AI and cloud partner push takes shape.
Oracle commits $1 billion over four years to strengthen its global partner network.
Expanded incentives target cloud migrations, AI applications, and partner training.
Oracle Marketplace gives partners more ways to sell specialized cloud solutions.
Oracle boosts partner tools to expand cloud adoption and long-term customer support.
Oracle Corporation announced a $1 billion investment in its partner network to expand cloud services and support growing artificial intelligence demand. The four-year commitment will strengthen partner capabilities across cloud infrastructure, business applications, and enterprise technology services. Meanwhile, Oracle (ORCL) stock rose 0.49% to $126.16, gaining $0.62, before slipping 0.03% to $126.12 after hours.
Oracle Corporation, ORCL
Oracle Commits $1 Billion to Expand AI and Cloud Partnerships
Oracle plans to direct its investment toward partner training, technical support, cloud migration, and business development programs. The company aims to help partners develop specialized solutions and expand their presence across enterprise markets. Additionally, Oracle will provide development environments and technical resources to support new applications and cloud services.
The investment covers Oracle PartnerNetwork, which connects software developers, systems integrators, cloud providers, resellers, and consulting firms. These businesses help customers deploy Oracle technology, modernize databases, and manage enterprise applications. Moreover, the expanded program will support Oracle Cloud Infrastructure, Fusion Applications, and related artificial intelligence services.
Oracle will also increase funding for certifications, product demonstrations, and joint sales activities across its partner ecosystem. Partners can use these resources to develop industry-specific applications, integrations, and automated business tools. Consequently, the company expects broader partner participation to strengthen cloud delivery capacity and customer reach.
Oracle Expands Cloud Services Through Partner Incentives
Oracle will direct part of its investment toward helping partners develop products and services using its technology. The company will offer testing environments, integration guidance, and technical assistance for specialized enterprise solutions. Furthermore, partners can combine their industry knowledge with Oracle platforms to address specific business requirements.
The expanded program also includes sales incentives, marketing support, and funding for eligible cloud migration projects. Oracle Marketplace will provide another channel for partners to commercialize software and reach enterprise customers. Meanwhile, additional training resources will help service providers manage database upgrades, application deployments, and cloud infrastructure projects.
Oracle also plans to strengthen customer support after initial technology deployments through its partner network. Its AI Success Navigator platform will help partners guide adoption, improve operations, and introduce additional capabilities. As a result, Oracle aims to support longer customer relationships and increase the use of its enterprise products.
Oracle (ORCL) Stock Advances as AI Investment Supports Cloud Growth
Oracle’s latest announcement strengthens its broader strategy to expand enterprise cloud adoption and artificial intelligence services. The company continues to build its technology ecosystem through partnerships with software developers and consulting firms. Furthermore, these relationships help Oracle reach businesses seeking cloud migration, automation, and database modernization services.
Oracle’s existing partnerships include Accenture and PwC, which support business modernization and enterprise technology projects. The company has also highlighted customer deployments involving Combe, Beca, and the Centre for Addiction and Mental Health. These projects demonstrate how Oracle combines enterprise applications with partner expertise across different industries.
The four-year commitment provides additional resources for partners to develop services and pursue enterprise cloud contracts. However, Oracle has not specified the investment’s expected revenue contribution or detailed annual spending schedule. The initiative expands Oracle’s partner development efforts while supporting its broader cloud infrastructure and enterprise software strategy.

The post Oracle (ORCL) Stock: Rises as $1 Billion AI Push Targets Cloud Expansion appeared first on Blockonomi.

TLDR
PURR stock climbs 1.15% to $8.78 after Hyperliquid expands its buyback to $100M.
Hyperliquid triples its repurchase capacity, lifting its buyback cap to $100M.
About $72M remains available for PURR share repurchases under the new plan.
Hyperliquid extends its PURR stock repurchase deadline to October 31, 2027.
PURR shares add 0.23% after hours, reaching $8.80 following Friday’s gains.
Hyperliquid Strategies expanded its stock buyback authorization to $100 million, lifting the previous $30 million cap. PURR stock gained 1.15% to $8.78, adding $0.10 after recovering from intraday lows near $8.60. Shares advanced another 0.23% to $8.80 after hours as the company updated its capital plans.
Hyperliquid Strategies Inc Common Stock, PURR
PURR Stock Gains Following Board Decision
The stock reversed an early decline during Friday’s session as buying strengthened later in the day. That recovery helped offset earlier selling and supported a positive close despite uneven trading. After-hours activity produced a smaller additional increase, continuing the upward move.
The board’s decision raises the maximum authorization by $70 million against its previous limit. The new amount more than triples the program’s original capacity for share purchases. Still, the authorization gives management permission to repurchase shares without requiring immediate purchases.
Hyperliquid Strategies focuses on digital asset treasury operations within the Hyperliquid ecosystem. The company uses capital management decisions to support its financial structure and broader treasury strategy. Accordingly, the buyback expansion adds flexibility to its existing approach to share management.
Hyperliquid Strategies Extends Buyback Deadline to 2027
The board extended the program’s end date from December 5, 2026, to October 31, 2027. The longer period gives management additional opportunities to consider purchases under changing market conditions. Meanwhile, approximately $72 million remains available under the expanded authorization.
The company may buy PURR shares on public markets at prevailing prices. Management may also arrange private transactions or use other methods allowed under federal securities law. The selected approach will depend on market circumstances, transaction terms and applicable requirements.
The company linked the decision to its long-term capital strategy and broader treasury framework. The increased limit allows management to evaluate purchases alongside other company capital needs. However, the company did not establish a fixed share count or transaction calendar.
What the $100 Million PURR Repurchase Plan Allows
Share repurchases allow businesses to acquire their own stock, potentially changing the number of outstanding shares. The effect depends on whether and how companies complete those transactions over time. An authorization alone creates no immediate change to outstanding shares.
Management will consider PURR’s trading price, general economic conditions and relevant legal restrictions. Those factors will shape the timing, size and total value of any future repurchases. The remaining allocation does not indicate an immediate cash commitment.
The company retains authority to extend, pause or end the program without advance notice. Accordingly, the final amount spent may differ from the authorized maximum at expiration. The expanded buyback capacity and extended deadline now form part of Hyperliquid Strategies’ capital management plans.

The post Hyperliquid Strategies Inc. (PURR) Stock: Shares Climb as Company Boosts Buyback Plan to $100M appeared first on Blockonomi.

TLDR
IONS stock slides 2.23% to $42.93 despite Roche’s Phase 3 kidney trial success.
Roche’s sefaxersen cuts proteinuria 43.1% in a key Phase 3 kidney disease trial.
Ionis shares rebound 2.33% after hours to $43.93 following regular-session losses.
Phase 3 data show stronger hematuria resolution with sefaxersen versus placebo.
Roche targets regulators as its kidney trial continues toward week 105 results.
Ionis Pharmaceuticals (IONS) stock fell 2.23% to $42.93, losing $0.98 during regular trading before rebounding 2.33% to $43.93 after hours. The decline came despite positive Phase 3 kidney disease trial results from its partner, Roche. The study showed that experimental treatment sefaxersen significantly reduced proteinuria in patients with primary IgA nephropathy.
\Ionis Pharmaceuticals, Inc., IONS
Roche Reports 43.1% Proteinuria Reduction in Phase 3 Kidney Trial
Roche reported positive results from the ongoing Phase 3 IMAgINATION study involving adults with primary IgA nephropathy. The trial evaluated sefaxersen alongside optimized standard care and compared its effectiveness against a placebo. At week 37, the treatment achieved a statistically significant 43.1% reduction in proteinuria relative to placebo.
The study recorded a 95% confidence interval between 32.5% and 52.0%, with a P-value below 0.0001. Researchers measured treatment effectiveness through the 24-hour urine protein-to-creatinine ratio, a key marker of kidney damage. Moreover, lower proteinuria levels generally correlate with better long-term kidney function.
Roche presented the findings during the American Society of Nephrology Kidney Week 2026 conference. Additionally, more patients receiving sefaxersen experienced resolution of blood in their urine compared with placebo recipients. The treatment also demonstrated consistent effectiveness across predefined patient subgroups without introducing new safety concerns.
Ionis Pharmaceuticals Advances Kidney Treatment Through Roche Partnership
Ionis developed sefaxersen as an RNA-targeted treatment that reduces factor B production in the liver. Factor B contributes to alternative complement pathway activity, which plays a role in IgA nephropathy. By reducing this protein, sefaxersen targets a biological process associated with kidney inflammation and damage.
The experimental medicine uses monthly injections beneath the skin and supports potential self-administration by patients. Meanwhile, Roche continues the blinded IMAgINATION study to measure changes in kidney function over two years. Researchers will assess estimated glomerular filtration rate at week 105 to evaluate longer-term treatment outcomes.
Roche licensed sefaxersen from Ionis under an agreement covering complement-mediated diseases. Ionis previously received upfront payments, licensing fees, and development milestone payments through the partnership. Furthermore, the agreement provides potential regulatory milestones, sales milestones, and tiered royalties on future net sales.
IONS Stock Declines as Roche Prepares Regulatory Discussions
Despite the clinical progress, Ionis shares finished regular trading lower before recovering part of their losses after hours. The contrasting price movements followed Roche’s announcement of the latest Phase 3 findings. However, the available trading information does not establish a specific cause for the regular-session decline.
IgA nephropathy causes progressive kidney damage and commonly affects adults before age 40. The disease affects at least 25 adults per million worldwide annually and can eventually cause kidney failure. Within 20 years of diagnosis, up to half of affected patients may develop end-stage kidney disease.
Roche plans to share the latest trial findings with health authorities to support further development discussions. Meanwhile, the ongoing study will provide additional evidence about sefaxersen’s effects on kidney function. Regulatory decisions and future commercial milestones will determine the treatment’s potential contribution to Ionis Pharmaceuticals’ business.

The post Ionis Pharmaceuticals (IONS) Stock: Falls 2.23% Despite Roche’s Breakthrough Phase 3 Kidney Trial Results appeared first on Blockonomi.

TLDR
GPUS stock jumps 34.05% to $0.1689 as Michigan AI data center launch approaches.
Hyperscale Data targets December 2026 to begin revenue-generating AI operations.
Company reaffirms its 2027 revenue forecast of $300 million to $350 million.
Hyperscale Data maintains its 2027 adjusted EBITDA forecast at $60M to $80M.
Preliminary Q3 revenue rises 64% to $40 million, driven by stronger operations.
Hyperscale Data, Inc. (GPUS) stock surged 34.05% to $0.1689, gaining $0.0429 as strong buying lifted shares before a late pullback. The rally followed the company’s reaffirmation of its 2027 revenue and earnings targets. Meanwhile, Hyperscale Data plans to launch revenue-generating AI operations at its Michigan campus in December 2026.
Hyperscale Data, Inc., GPUS
Hyperscale Data Reaffirms $350 Million Revenue Target for 2027
Hyperscale Data maintained its preliminary 2027 revenue forecast between $300 million and $350 million. The company also expects adjusted earnings before interest, taxes, depreciation, and amortization between $60 million and $80 million. These projections reflect anticipated growth across its operating businesses and planned infrastructure expansion.
The company operates across three main business platforms, including data centers, financial services, and portfolio investments. Its Ault Capital Group subsidiary manages lending, digital assets, and several portfolio businesses. Hyperscale Data continues expanding its AI infrastructure operations to support future revenue growth.
Management based its financial targets on expected customer deployments, financing arrangements, and business performance. However, the projections depend on successful development and execution across several operating divisions. The company also expects its digital asset activities to contribute to its broader financial performance.
Michigan AI Data Center Targets December 2026 Operations
Hyperscale Data expects to energize its first AI computing capacity at its Michigan campus in December 2026. The company plans to begin generating revenue alongside the initial deployment of computing infrastructure. This milestone will mark an important expansion of its AI data center business.
The Michigan project forms part of the company’s broader strategy to develop additional computing capacity. Moreover, management expects future expansion as customer deployments advance and infrastructure development progresses. The company aims to secure the necessary resources and complete planned development milestones.
Chief Executive Officer William Horne reported progress across the company’s businesses ahead of the planned Michigan launch. Management continues prioritizing contracted computing capacity and the financing needed to support infrastructure development. Additionally, the company expects its expanding operations to strengthen its position in the AI infrastructure market.
Hyperscale Data Reports 64% Preliminary Quarterly Revenue Growth
Hyperscale Data previously reported preliminary third-quarter 2026 revenue of approximately $40 million. This represented a 64% increase from the $24.3 million recorded during the same quarter in 2025. Stronger crane operations, defense activities, lending, and trading supported the increase.
The company also benefited from software revenue associated with blockchain network operations. Additionally, the reconsolidation of Gresham Worldwide contributed to higher defense revenue during the quarter. However, declining Bitcoin mining revenue partly offset growth across the other business segments.
Hyperscale Data has not completed its independent audit or review of the preliminary quarterly figures. Therefore, final results may differ as the company completes its financial closing procedures. Meanwhile, management continues pursuing AI infrastructure expansion, tokenization opportunities, and digital asset operations to support its 2027 financial targets.

The post Hyperscale Data, Inc. (GPUS) Stock: Soars 34% as Michigan AI Data Center Nears December Launch appeared first on Blockonomi.

TLDR
EDBL slides 1.32% as a Tennessee farm partnership fails to spark a stock rebound.
Caney Fork Farms deal targets more than 12% savings on selected herb production.
Edible Garden targets herb margins above 19%, up from about 4% on shifted output.
Production transfers begin in late 2026, with most changes planned for 2027.
GreenThumb 2.0 will help connect farm output, inventory, and retail demand.
A Tennessee farm agreement failed to lift Edible Garden AG shares despite the company’s planned production overhaul. EDBL stock dropped 1.32% to $0.8399, losing $0.0112 as early gains faded Friday. Meanwhile, the partnership targets gross margins above 19% on selected herb production.
Edible Garden Partners With Caney Fork Farms to Expand Production
Edible Garden signed a supply agreement with Caney Fork Farms, an organic producer in Carthage, Tennessee. The partner will handle selected growing activities that Edible Garden currently manages within its herb business. This adds outside production capacity to its existing national supply network.
The arrangement combines Edible Garden’s controlled-environment expertise with Caney Fork Farms’ regenerative growing methods. Moreover, it adds a Tennessee location to support retail orders and changing demand. Edible Garden plans a phased transfer to protect product quality and delivery schedules.
The transition starts in the fourth quarter of 2026 and continues into 2027. The company expects to complete most production transfers during the following year, 2027. Throughout the process, Edible Garden will maintain food safety, freshness, and fulfillment standards.
Edible Garden Targets Lower Production Costs and Higher Gross Margins
The agreement shifts selected growing expenses toward a model that responds more directly to demand. Consequently, Edible Garden expects savings on labor, energy, maintenance, and other production costs. The company projects cost reductions above 12% for the affected activities.
Edible Garden estimates margins on transferred production could rise from roughly 4% to above 19%. These figures apply to selected growing activities, not the company’s entire business. The arrangement also aims to increase output without proportionate increases in operating expenses.
Financial results will depend on transfer timing, customer orders, changing seasonal needs, and production volumes. Additionally, shifts in product mix and operating conditions could change the savings achieved. Edible Garden expects efficiency improvements to develop gradually as implementation progresses.
GreenThumb 2.0 Technology Supports Edible Garden’s Expansion Plans
Edible Garden will use its GreenThumb 2.0 platform to coordinate the expanded supply network. The technology supports demand forecasts, inventory management, production planning, and product traceability. These tools will connect farm output with retailer orders as responsibilities shift.
Beyond herbs, the partners plan to explore regeneratively grown crops and functional ingredients. They also aim to develop products for Edible Garden’s Farm-to-Formula platform. The potential expansion could create additional offerings for existing retail customers in multiple product categories.
Edible Garden supplies organic and sustainable produce through its controlled-environment agriculture operations. Its Zero-Waste Inspired mission emphasizes resource efficiency across agricultural production and distribution. Caney Fork Farms contributes organic farming experience and soil conservation practices as Edible Garden works toward profitability.

The post Edible Garden AG (EDBL) Stock Falls Despite New Farm Partnership Targeting 19% Gross Margins appeared first on Blockonomi.

TLDR
RKLB stock jumps 2.28% to $52.39 following another successful Electron launch.
Rocket Lab completes its 98th Electron flight, moving closer to 100 launches.
Three HawkEye 360 satellites head to low Earth orbit after New Zealand liftoff.
Rocket Lab records its 19th successful mission of 2026 with HawkEye 360 in NZ.
HawkEye 360 expands satellite coverage for maritime and radio signal monitoring.
Rocket Lab Corporation (RKLB) stock climbed 2.28% to $52.39, gaining $1.17 as shares recovered from intraday lows near $49.70. The increase followed Rocket Lab’s successful Electron rocket launch for HawkEye 360 from New Zealand. The mission marked another milestone for the company’s growing satellite launch operations and expanding commercial partnerships.
Rocket Lab USA, Inc., RKLB
Rocket Lab Completes 98th Electron Launch for HawkEye 360
Rocket Lab launched its Electron rocket from Launch Complex 1 in New Zealand on October 23, 2026. The mission, named We’re Not Hawking Around, lifted off at 8:11 p.m. New Zealand daylight time. The rocket carried three HawkEye 360 satellites toward a planned low Earth orbit at an altitude of 520 kilometers.
The launch marked Electron’s 98th flight and Rocket Lab’s 19th successful mission of 2026. Additionally, the company moved closer to completing 100 Electron launches since the rocket entered commercial service. This milestone highlights Rocket Lab’s continued activity in the dedicated small satellite launch market.
Rocket Lab also completed its third dedicated Electron mission for HawkEye 360 through the latest launch. The partnership supports HawkEye 360’s efforts to expand its satellite network and strengthen global radio frequency monitoring. Furthermore, repeated missions demonstrate Rocket Lab’s ability to support customers with ongoing satellite deployment requirements.
HawkEye 360 Expands Satellite Network for Global Monitoring
HawkEye 360 operates satellites that collect and analyze radio frequency signals from locations across the world. Its satellites work in groups of three to identify signals and determine their sources. The latest deployment adds another group of spacecraft to support the company’s intelligence and monitoring services.
The satellite network supports maritime tracking, communications mapping, radar monitoring, and detection of navigation signal interference. Its technology helps identify Global Navigation Satellite System jamming that can disrupt positioning services. These capabilities support commercial operations, maritime security, and defense-related monitoring activities.
Rocket Lab provides dedicated launch services that allow satellite operators to select specific deployment schedules and orbital destinations. Unlike larger shared missions, dedicated launches give customers greater control over their satellite deployment plans. Consequently, HawkEye 360 can coordinate its constellation expansion with its operational requirements and planned coverage areas.
RKLB Stock Gains as Rocket Lab Strengthens Launch Operations
Rocket Lab’s latest mission adds to its growing record of Electron launches throughout 2026. The company continues to serve commercial satellite operators and organizations with defense and intelligence requirements. Meanwhile, its expanding launch activity reflects sustained demand for reliable access to low Earth orbit.
Electron specializes in launching smaller spacecraft, allowing Rocket Lab to serve customers with specific mission requirements. The company also develops space systems and satellite components alongside its established launch business. This combination supports its position across different segments of the growing space industry.
Rocket Lab now approaches its 100th Electron launch following another successful mission for HawkEye 360. Its latest achievement reinforces the company’s operating record and established relationship with a repeat customer. The stock’s recovery also coincided with another milestone in Rocket Lab’s commercial launch program.

The post Rocket Lab (RKLB) Stock: Surges as Electron Completes 98th Launch for HawkEye 360 in New Zealand appeared first on Blockonomi.

TLDR:
Pentagon bans military and civilian personnel from using nonpublic information to trade on Polymarket and Kalshi.
The directive covers classified and unclassified information, including trades made indirectly through third parties.
Defense Secretary Pete Hegseth warns that military-related bets could expose sensitive operations to foreign intelligence services.
Violations may result in administrative, disciplinary, or criminal action under military rules and federal law.
The Pentagon has banned military and civilian personnel from trading with nonpublic information on prediction markets, including Polymarket and Kalshi. Defense Secretary Pete Hegseth issued the directive on October 20 to senior Pentagon leaders and combatant commanders. The order covers classified and unclassified information, with disciplinary or criminal penalties possible for violations.
Pentagon Ban Covers Trading With Nonpublic Military Information
Hegseth’s memorandum prohibits department personnel from using information unavailable to the public for financial transactions. The restriction covers trades placed directly or through another person, and it applies beyond prediction markets.
Traditional betting platforms and other financial markets fall under the same rule when personnel use nonpublic information. The directive does not prohibit every lawful trade by service members, but it bars transactions based on privileged knowledge.
Hegseth bars US forces from using undisclosed information to bet on Polymarket, Kalshihttps://t.co/dVs3hvi8Pk
— The Hill (@thehill) October 22, 2026
Hegseth warned that foreign intelligence services could study trading patterns to identify potential U.S. military actions. “Our enemies watch movements in these markets,” he wrote, referring to financial activity around military outcomes.
He said bets on operation dates or military results could reveal information about troop movements, targets, and timing. The memorandum further warned that financial positions could influence the judgment of military analysts and logistics personnel.
Violators may face administrative measures, military discipline, or criminal prosecution under federal law or the Uniform Code of Military Justice.
Military Insider Trading Case Fuels Scrutiny of Polymarket
The order follows an April enforcement case involving U.S. Army Master Sergeant Gannon Ken Van Dyke. Federal authorities accused him of using classified details about the operation to capture Venezuelan leader Nicolás Maduro. According to the CFTC, his alleged Polymarket trades generated more than $404,000 in profits.
Prosecutors said he placed about $33,000 in wagers before the January military operation became public. Van Dyke pleaded not guilty to the charges, and the allegations remain subject to court proceedings. The CFTC separately filed a civil complaint concerning his alleged misuse of government information.
Questions about advance knowledge have extended beyond that case, including bets placed before U.S. strikes on Iran. Six recently created Polymarket wallets reportedly earned nearly $1 million, prompting questions about the timing of their positions. Those transactions drew scrutiny, though available reports did not establish that the traders had classified information.
Congress Examines Prediction Market Insider Trading Controls
Congress has been examining how prediction platforms detect and stop trading based on confidential information. On May 22, House Oversight Chairman James Comer opened an investigation into Polymarket and Kalshi.
The committee sought records about identity checks, suspicious trades, and the companies’ methods for enforcing market rules. Its inquiries followed concerns that government officials could use restricted information to profit from contracts on public events.
Kalshi has faced separate questions about potential insider activity in political markets, including bets preceding a White House appointment. The platform confirmed an inquiry into those wagers, but no public finding had established wrongdoing in that case.
Kalshi has introduced employment disclosures for some higher-risk markets, while its surveillance team reviews suspicious activity. Polymarket has also said it cooperated with investigators in the Van Dyke case.
Hegseth’s October 20 directive now sets out a department-wide rule covering military and civilian staff. It directs personnel to avoid using nonpublic information for personal gain, whether trading themselves or through other parties.
The post Pentagon Bans Military Personnel From Insider Trading on Polymarket and Kalshi appeared first on Blockonomi.

TLDR:
New York AG seeks $1.37 billion from NovaTech founders Cynthia and Eddy Petion over alleged crypto fraud.
Investors deposited $1.16 billion, but only $25.99 million reached trading, resulting in $18.19 million in losses.
Investigators traced at least $134.5 million to founders’ wallets as NovaTech allegedly promised 2%–4% weekly returns.
Four NovaTech promoters agreed to pay nearly $6 million and accepted permanent financial industry bans.
New York Attorney General Letitia James has asked a court to order NovaTech’s founders to pay $1.37 billion. The founders, Cynthia and Eddy Petion, previously faced crypto pyramid scheme charges over an investment operation that collected funds from customers worldwide.
The October 22 filing seeks disgorgement and interest, while four NovaTech promoters have agreed to pay nearly $6 million. More than 11,000 New Yorkers invested in NovaTech and AWS Mining, according to the attorney general’s office.
New York Seeks $1.37B Following NovaTech Default Judgment
The court filing seeks $1.1345 billion in disgorgement and $232.47 million in prejudgment interest. Together, those amounts total $1.367 billion, which New York wants the founders and NovaTech entities to pay.
The request follows an August 2025 default judgment after the petition failed to respond to the state’s lawsuit. The court barred their securities, commodities, and crypto activities in New York but deferred its decision on financial relief.
New York AG Seeks $1.37B From NovaTech Founders Over Alleged Crypto Ponzi Scheme
New York AG seeks $1.37 billion from NovaTech founders Cynthia and Eddy Petion: $1.13 billion in disgorgement plus $232.5 million in prejudgment interest. Court filings show $1.16 billion in crypto… pic.twitter.com/XDjGMonCXs
— Wu Blockchain (@WuBlockchain) October 23, 2026
James said the businesses drew investors into fraudulent schemes by promising returns from mining and crypto trading. She accused the operators of robbing investors of their life savings while targeting religious and immigrant communities.
In a separate proceeding, a federal court ordered repayments in a $31.48 million crypto fraud case last month. For NovaTech, the requested amount still requires a court decision following the state’s October filing.
NovaTech Investors Deposited $1.16B, but Little Reached Trading
Between August 2019 and May 2023, investors deposited $1.1605 billion in cryptocurrency into NovaTech wallets tracked by CoinPayments. Court records show only $25.99 million reached a trading platform, where losses totaled $18.19 million.
Prosecutors allege NovaTech promised weekly returns of 2% to 4%, despite having little trading income to support those claims. The company allegedly used deposits from new investors to pay other customers and provide bonuses for recruitment.
Investigators traced at least $134.5 million in transfers to wallets belonging to Cynthia and Eddy Petion. The company recruited through social media, WhatsApp chats, and prayer groups, including Haitian communities in New York.
Federal regulators described WhatsApp-based crypto investment fraud in another case that resulted in a June judgment. A separate 2026 crypto Ponzi prosecution concerned alleged payouts funded by new deposits instead of trading profits.
NovaTech collapsed in 2023, leaving tens of thousands of investors unable to recover their cryptocurrency. New York’s filing describes losses among customers across the United States and abroad.
Four NovaTech Promoters Agree to Nearly $6M in Repayments
New York settled claims against Martin Zizi, Frantz Ciceron, Ricardo Roy Sr., and James Corbett over their roles as promoters. The agreements require approximately $5.98 million in payments and permanently bar all four from securities, commodities, and cryptocurrency activities.
Zizi agreed to pay $2.9 million, while Ciceron will pay $2.05 million under the settlements. Corbett will pay $750,000, and Roy’s payment is $275,861, with the funds intended to benefit victims.
The case began with a June 2024 lawsuit against NovaTech, AWS Mining, and several people associated with both operations. AWS Mining collapsed in 2019 after promising monthly returns of 15% to 20%, and the Petions later established NovaTech.
The CFTC has pursued other alleged crypto and forex Ponzi schemes involving recruitment bonuses. In New York, the court must still decide the $1.37 billion request against the Petions and NovaTech entities.
The post New York AG Seeks $1.37B From NovaTech Founders Over Alleged Crypto Ponzi Scheme appeared first on Blockonomi.

TLDR:
Bitcoin price faces macro pressure as Brent holds above $100, with Darkfost warning that expensive energy could constrain fresh liquidity.
CryptoQuant analysis links sustained oil strength above its annual average with slower Bitcoin momentum, without establishing direct causation.
Lookonchain reported that 40 newly created wallets withdrew 9,458 BTC, valued at approximately $771.5 million, through Wintermute since October 1.
Large wallet withdrawals suggest potential accumulation, although the transfers do not confirm fresh purchases or identify the ultimate owners.
Bitcoin price faces a tougher economic backdrop as Brent crude trades above $100, raising concerns about inflation and market liquidity. CryptoQuant analyst Darkfost says prolonged oil strength has often coincided with slower Bitcoin momentum, although the relationship does not establish causation.
Meanwhile, large holders continue moving substantial amounts of BTC through Wintermute. Lookonchain reported that 40 newly created wallets withdrew 9,458 BTC, worth approximately $771.5 million, since October 1.
The activity suggests potential accumulation despite weak trading conditions. However, those withdrawals do not establish whether fresh purchases occurred or whether the addresses belong to separate institutional investors or wealthy individuals.
Bitcoin Price Faces Liquidity Risks as Brent Holds Above $100
Darkfost attributed elevated oil prices to continuing Gulf tensions and intensified Ukrainian attacks on Russian refineries. Higher energy costs can spread across manufacturing, transport and services, adding pressure throughout the economy.
Bitcoin faces a tough macro backdrop as Brent holds above $100
“Over the long term, we can see that when Brent settles into a strong upward trend, above its annual average, Bitcoin has often slowed down.” – By @Darkfost_Coc pic.twitter.com/LR7SfmXyUm
— CryptoQuant.com (@cryptoquant_com) October 23, 2026
Brent crude stood around $104 in the analysis, compared with roughly $60 to $70 earlier in 2026. Its moving average over 365 days had also started rising after a prolonged decline.
The chart tracks Bitcoin and Brent back to 2014. Shaded periods identify stretches when oil traded above its annual average, highlighting several overlaps with weaker cryptocurrency performance.
Examples include 2018, parts of 2021 and 2022, and periods during 2026. The Bitcoin price did not decline during every instance of rising oil, making the distinction between correlation and causation important.
Darkfost argues that the surrounding economic conditions matter more than oil movements alone. Persistent inflation can constrain liquidity and reduce the capital available for assets carrying greater risk.
Higher energy prices may also complicate Federal Reserve decisions on interest rates. If inflation remains elevated, policymakers could have less room to ease financial conditions.
That would leave the Bitcoin price facing a less supportive environment for fresh investment. Sustained borrowing costs and elevated yields can affect how investors allocate capital across markets.
Still, Darkfost said Bitcoin benefited when macro pressure briefly eased in July. Oil subsequently rebounded, but he did not suggest that further cryptocurrency gains had become impossible.
Capital can shift between markets even without substantial new inflows. The analyst emphasized sustained trends rather than individual daily price fluctuations. His warning concerns the difficulty of attracting fresh liquidity while energy costs remain high.
Whale Withdrawals Top $770 Million amid Weak Market Momentum
Bitcoin whales offer another view of market activity during the price slowdown. The 40 wallets tracked by Lookonchain received their BTC through Wintermute over the period beginning October 1.
Whales are accumulating $BTC!
Since Oct 1, 40 newly created wallets have withdrawn 9,458 $BTC ($771.5M) from #Wintermute.https://t.co/AR7qxcyoiU pic.twitter.com/TfzSTKz7UF
— Lookonchain (@lookonchain) October 23, 2026
The reported withdrawals exceeded $770 million, a substantial movement despite recent price weakness. They suggest that some large participants remain willing to hold Bitcoin through uncertain conditions.
However, transfers reveal less about demand than completed purchases with identifiable counterparties. The available information does not establish transaction prices, ownership or whether one entity controls several receiving addresses.
For the Bitcoin price, that distinction limits how strongly the activity supports a bullish interpretation. Moving coins into new wallets does not demonstrate that buying pressure exceeds selling across the market.
The oil analysis and wallet data also measure different developments. Brent crude provides context for inflation and liquidity, while wallet withdrawals track the movement of existing cryptocurrency holdings.
Bitcoin whales may accumulate during difficult economic periods without producing an immediate market recovery. Their activity can coexist with weak momentum when other participants reduce exposure or when broader demand remains limited.
The Bitcoin price therefore has no confirmed recovery target from either observation. Neither the wallet transfers nor the historical oil comparison establishes a timetable for a rebound.
Darkfost identified persistent oil strength above its annual average as the condition to monitor. A retreat below $100, followed by a move beneath that average, could ease the pressure described in the analysis.
The post Bitcoin Price Faces Oil Pressure as Whale Transfers Top $770M appeared first on Blockonomi.

TLDR
Malaysia and Thailand join Singapore’s BLOOM initiative as policymaker members.
The initiative focuses on cross-border payments using stablecoins and tokenized bank deposits.
Ripple, Visa, Mastercard and the World Bank Group are among the participating organizations.
Ripple and Unloq plan to test automated trade payments using RLUSD on the XRP Ledger.
Central banks will examine payment settlement, network compatibility, identity checks and regulatory controls.
Singapore has expanded its BLOOM payments initiative as Malaysia and Thailand join efforts to test cross-border transfers. The work covers regulated stablecoins and tokenized bank deposits.
Singapore Adds Two Central Banks to BLOOM
The Monetary Authority of Singapore confirmed the membership of Bank Negara Malaysia and the Bank of Thailand on Friday. Both joined as policymaker members rather than commercial payment providers.
BLOOM stands for Borderless, Liquid, Open, Online, Multi-currency. Singapore started the project in October 2025 to bring regulators, banks and technology firms together around digital money settlement.
Ripple and Payment Networks Join the Work
Current participants include Ripple, Visa, Mastercard, Airwallex, Maybank and the World Bank Group. Circle, Coinbase, JPMorgan, Standard Chartered and Stripe were already involved in the initiative.
Ripple announced a trial with trade finance company Unloq in March. The partners plan to use RLUSD on the XRP Ledger and release payments when shipment conditions are met. Separately, Cross River Bank is adding Ripple’s RLUSD to its payment system.
The World Bank Group brings experience in international payment systems and financial inclusion. BLOOM participants are examining business payments, company cash management and trade finance.
Banks Examine Settlement and Safety Checks
The central banks will examine how institutions accept and exchange different digital currencies across countries. They will study ways for payment systems to communicate without requiring separate deals in every market.
Tokenized deposits form another part of the work. These tokens represent bank deposits rather than stablecoins issued by private companies. In a separate development, JPMorgan made its JPM Coin deposit token available on Ethereum this week for approved institutional clients.
BLOOM will examine identity checks, sanctions screening and transaction limits. MAS said common operating arrangements could reduce implementation costs while allowing regulators to apply their own national requirements.
Malaysia and Thailand Outline Their Priorities
Bank Negara Malaysia Deputy Governor Aznan bin Abdul Aziz said payments using different forms of digital money were becoming more practical. He welcomed cooperation between central banks and companies.

Rules remain a separate issue for stablecoin providers. This week, the US banking regulator outlined waiver requirements for existing stablecoin issuers, showing how oversight differs between markets. Bank of Thailand Deputy Governor Daranee Saeju said Singapore’s initiative would support its work on rules for tokenized money.
The post Malaysia, Thailand Join Singapore’s Cross-Border Payment Push appeared first on Blockonomi.